Clinical Research Programs in Co-tuberculosis Infections
There are three Tuberculosis (TB) studies currently being conducted in adults of which one still needs additional funding. HIV-NAT is currently participating in the TB network. TB studies emerging from the network address issues pertaining to the country with the aim to improve the TB care in the country so that we can reduce TB mortalities by half by 2015 as per the Millenium Development Goals. Working with various Chest Units from the different hospitals have been fruitful in accomplishing this goal.
“TB is a major global health problem, a leading cause of death in HIV infected persons and the burden is especially high in Asia and Africa. Successful TB control involves early case detection and diagnosis through quality-assured methodology, provision of safe and efficacious treatment and a system that support quality patient care and supervision. The management of HIV and TB co-infection is further complicated by complex interactions between drugs used to treat both conditions. Thus HIV-NAT has conducted the following studies.”– Denise Hsu
This is a pilot study of the pharmacokinetics and safety of lopinavir/ritonavir 400/100mg bid versus lopinavir/ritonavir 600/150 mg BID combined with nucleoside analogue reverse transcriptase inhibitors in HIV/TB co-infected patients receiving rifampicin containing anti-tuberculosis therapy.
Optimize TB Treatment outcome in Tertiary Care Hospitals
Regional TB Study
Socio-Economic Determinants of Tuberculosis (TB), Multidrug-resistant TB, and Immune Reconstitution Syndrome in HIV-TB Co-infected Patients in Asia
© Copyright 2012 HIV-NAT. All Rights Reserved.
The HIV Netherlands Australia Thailand Research Collaboration